Advisor Net Financial, Inc Bei Gene, Ltd. Transaction History

Advisor Net Financial, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 12, 2024	BUY	$141.8 - $181.47 $283 - $362	2 New	2 $0
Q3 2022 Oct 04, 2022	SELL	$131.8 - $202.24 $1,054 - $1,617	-8 Reduced 80.0%	2 $0
Q2 2022 Jul 07, 2022	SELL	$121.11 - $216.05 $363 - $648	-3 Reduced 23.08%	10 $2,000
Q1 2022 Apr 14, 2022	BUY	$146.52 - $269.56 $586 - $1,078	4 Added 44.44%	13 $2,000
Q3 2021 Oct 15, 2021	BUY	$249.6 - $403.14 $2,246 - $3,628	9 New	9 $3,000
Q2 2020 Aug 26, 2020	SELL	$123.9 - $195.41 $22,302 - $35,173	-180 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$115.78 - $208.34 $20,840 - $37,501	180 New	180 $30,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Advisor Net Financial, Inc, based on Form 13F filings with the SEC.

Stay updated on Advisor Net Financial, Inc with notifications on news.